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Abstract:
In this paper we consider the problem in causal inference of estimating the local com-
plier average causal effect (CACE) parameter in the setting of a randomized clinical trial
with a binary outcome, cross-over noncompliance, and unintentional missing data on the
responses. We focus on the development of a moment estimator that relaxes the as-
sumption of latent ignorability and incorporates sensitivity parameters that represent the
relationship between potential outcomes and associated potential response indicators. If
conclusions are insensitive over a range of logically possible values of the sensitivity pa-
rameters, then the number of interpretations of the data is reduced, and causal conclusions
are more defensible. We illustrate our methods using a randomized encouragement design
study on the effectiveness of an influenza vaccine.
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1. Introduction
Well-designed randomized clinical trials are a powerful tool for investigating causal relationships and
producing valid estimates of a causal effect of treatment. But in trials involving human subjects there are
oftentimes problems of noncompliance and missing data which standard analyses either ignore, which can
lead to biased estimators, or account for in such a way that the estimand can no longer be considered a causal
effect. Rubin developed an approach to causal inference using potential outcomes (Rubin (1974, 1978)) that
has been referred to as the Rubin Causal Model (Holland (1986)). This model provides a framework for
defining the parameters of interest and correctly attributing the data observed between different treatment
groups to causal effects of the treatments.
Method-of-moment estimators are useful in understanding where information comes from within the
observed data and what assumptions help to identify the estimands of interest. Frangakis and Rubin (1999)
developed a moment estimator for the complier average causal effect (CACE) in a setting where there was
unintentional missing data and only the intervention group could receive the new treatment. Zhou and Li
(2006) later extended these moment methods to a setting of cross-over noncompliance (i.e. intervention
and control subjects could receive the new treatment) and missing data. This paper extends the results
of Zhou and Li (2006) by developing the asymptotic theory for their moment estimator and examining
its performance in finite samples and under deviations from model assumptions in the setting of a binary
response, cross-over noncompliance, and unintentional missing data on the responses. This paper also focuses
on the development of a moment estimator that relaxes the assumption of latent ignorability and incorporates
sensitivity parameters that represent the relationship between potential outcomes and associated potential
nonresponse indicators. These parameters are assumed known, and are allowed to take on a plausible range of
values in order to assess the sensitivity of the conclusions to varying assumptions regarding this relationship.
Sections 2-4 introduce the setting, notation, and assumptions. In Section 5 we give the results of Zhou
and Li (2006) for a CACE estimator derived under the assumption of latent ignorability, and we extend
their results by deriving the asymptotic distribution of their estimator. Section 6 provides simulation results
that examine the finite sample properties of the estimator under conditions that follow the assumptions, and
then under certain deviations from these assumptions. In Section 7 we derive the CACE estimator and its
asymptotic distribution when the latent ignorability assumption is relaxed and sensitivity parameters are
introduced. In Section 8 we illustrate our methods using a randomized encouragement design study on the
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effectiveness of an influenza vaccine.
2. Setting and Notation
The setting consists of a clinical trial with N subjects assigned to treatment Z, where Z is an N -vector of
treatment assignments with ith element Zi. In this setting Zi = 1 if subject i is assigned the new treatment,
and Zi = 0 if assigned the control. LetDi be the treatment received under the observed treatment assignment,
where Di = 1 if subject i received the new treatment and Di = 0 if subject i received the control. Then
let D(Z) be the vector of potential treatment receipts given the vector of treatment assignments Z with ith
element Di(Z). Let Yi be the binary outcome for subject i under the observed treatment assignment and let
Yi(Z) be the binary potential outcome given the vector for treatment assigments Z.
Let Ri be the binary indicator for response under the assigned treatment, equal to 1 if response Yi was
observed for subject i and 0 otherwise. Then let Ri(Z) be the binary indicator for response equal to 1 if
response Yi(Z) was observed for subject i and 0 otherwise, for a given vector of treatment assignments Z.
Then a random subset of the N subjects are assigned to treatment arm Z. Table 1 provides a summary of
the notation used throughout the paper.
3. Definition of Causal Estimands
We make the stable unit treatment value assumption (SUTVA) which allows us to write the potential
outcomes as functions of Zi rather than of the entire vector Z. Formally the SUTVA states that Di(Z) equals
Di(Z
′
), Yi(Z) equals Yi(Z
′
), and Ri(Z) equals Ri(Z
′
) if Zi = Z
′
i which means that we can write Di(Z), Yi(Z),
and Ri(Z) as Di(Zi), Yi(Zi), and Ri(Zi), respectively. Under the SUTVA we can define the intention-to-treat
(ITT) causal effect of Z on D as E[Di(1)−Di(0)].
We assume that compliance is all-or-none, meaning that any switching of treatments was done soon after
randomization so that the subject is assumed to have completely taken the new treatment or the control. We
can stratify the population into four compliance principal strata (Frangakis and Rubin (1999)) as determined
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by the value of the vector [Di(0), Di(1)], where
Ci =


n (never-taker) if Di(0) = Di(1) = 0
a (always-taker) if Di(0) = Di(1) = 1
c (complier) if Di(0) = 0 and Di(1) = 1
d (defier) if Di(0) = 1 and Di(1) = 0
Note that unlike membership to the observed compliance strata, membership to these principal compliance
strata (referred to as compiance types for the remainder of the paper) is unaffected by assigned treatment
and therefore can be considered as a baseline covariate (Frangakis and Rubin (2002)). For our setting we
make the assumption of monotonicity (Imbens and Angrist (1994)), where Di(1) ≥ Di(0) for all subjects
(i.e. there are no defiers) where compliance type is observable when Zi 6= Di. Here subjects with observed
Zi = Di = 0 are a mixture of compliers and never-takers, and subjects with observed Zi = Di = 1 are a
mixture of compliers and always-takers.
Let ψtzd = P [Ci = t|Zi = z, Di = d] be the probability of compliance type t given the assigned treatment
z and received treatment d, and let ηzt = E[Yi(z)|Zi = z, Ci = t] be the conditional expectation of the
outcome given treatment assignment z and compliance type t. Then, under the monotonicity assumption,
we define the ITT effect as ITT =
∑
t∈{n,a,c}ωtITTt where ωt = P (Ci = t) and ITTt = E[Yi(1)−Yi(0)|C = t]
is the average ITT effect of Z on Y for the subpopulation of compliance type t. Noncompliers (never-takers
and always-takers), by definition, do not carry information about the comparison between treatments. Thus
we focus on the the subpopulation of compliers and define the complier average causal effect (CACE) to be
ITTc, or
CACE = E[Yi(1)− Yi(0)|Ci = c] = η1c − η0c,
which is the treatment effect among the subpopulation of compliers and the focus of the remainder of the
paper. Table 1 provides a summary of the notation used throughout the paper.
4. Additional Assumptions
In addition to the SUTVA and monotonicity, there are two assumptions that are sometimes plausible
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and that help facilitate inference: the compound exclusion restriction for never-takers and always-takers
(Frangakis and Rubin (1999)) which generalizes the standard exclusion restriction (Angrist, Imbens, and
Rubin (1996); Imbens and Rubin (1997)); and latent ignorability (Frangakis and Rubin, 1999). The com-
pound exclusion restriction states that among the subpopulation of never-takers or always-takers, treatment
assignment does not affect potential outcomes or missing data distributions, or P [Yi(1), Ri(1)|Ci = n] =
P [Yi(0), Ri(0)|Ci = n] and P [Yi(1), Ri(1)|Ci = a] = P [Yi(0), Ri(0)|Ci = a]. Next we invoke a latent ignora-
bility assumption which states that, within each latent compliance type, potential outcomes and associated
potential response indicators are independent, or P [Ri(1), Ri(0)|Yi(1), Yi(0), Ci] = P [Ri(1), Ri(0)|Ci]. We
make the assumption of latent ignorability here because it is more plausible than the assumption of standard
ignorability (Rubin (1978); Little and Rubin (1987)).
5. Asymptotic Theory of the CACE Moment Estimator
Under the SUTVA, monotonicity assumption, latent ignorability, and the compound exclusion restriction
for never-takers and always-takers, the CACE is identifiable and Zhou and Li (2006) derived the following
moment estimators
ηˆ1c =
∑
YiRiZiDi −
∑
YiRi(1− Zi)Di∑
RiZiDi −
∑
Ri(1− Zi)Di ; ηˆ0c =
∑
YiRi(1− Zi)(1−Di)−
∑
YiRiZi(1−Di)∑
Ri(1− Zi)(1−Di)−
∑
RiZi(1−Di) .
Then the estimator for the CACE computed by Zhou and Li (2006) is ̂CACELI = ηˆ1c − ηˆ0c. Note that
in the first summation for ηˆ1c, contributions come from subjects with Zi = Di = 1, which consist of a
mixture of compliers and always-takers. Since we are interested in the average among compliers, the averages
for the always-takers (in the second term) are subtracted. Note that Imbens, Angrist, and Rubin (1996)
develop an equivalent estimator for the case where there are no missing outcomes (i.e. Ri = 1 for all
subjects) under the assumptions of SUTVA, monotonicity, and an exclusion restriction on outcomes only.
Let pizd = P (Ri = 1, Zi = z, Di = d) denote the joint probability of observing the response with treatment
assignment z and treatment receipt d; and let vzd = P (Yi = 1, Ri = 1, Zi = z, Di = d) denote the joint
distribution of observing outcome Y = 1 with treatment assignment z and treatment reciept d. The following
theorem, proved in the online appendix (http://www.stat.sinica.edu.tw/statistica/submission) using the delta
method, forms a basis for inference about the estimator.
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Theorem 5.1. Under the assumptions of Section 3,
√
n( ̂CACELI −CACE)→d N (0, (V0+ V1) 12 )
as n →∞, where
V0 =
A2(3pi10 − pi00) + A(pi00 − pi10 − 4v10) + 2v10
(pi00 − pi10)2 ,
V1 =
B2(3pi01 − pi11) + B(pi11 − pi01 − 4v01) + 2v01
(pi11 − pi01)2 ,
for A = (v00 − v10)/(pi00− pi10) and B = (v11 − v01)/(pi11− pi01).
Then for N subjects in the study, by defining 1
N
∑n
i=1 Ri1[Zi=z,Di=d] and
1
N
∑n
i=1 YiRi1[Zi=z,Di=d] to be the
usual sample estimates for pizd and vzd, respectively, and letting Vˆ0 and Vˆ1 be the corresponding estimators
for V0 and V1, respectively,
√
n( ̂CACELI − CACE)(Vˆ0 + Vˆ1)− 12 →d N (0, 1)
6. Simulation Study
In this section we examine some finite sample properties of this estimator, first under hypothetical con-
ditions that follow the assumptions of latent ignorability and the compound exclusion restriction, and then
under certain deviations from latent ignorability.
6.1. Numerical Results Under Latent Ignorability and the Compound Exclusion Restriction
The N = 300 subjects were randomized to the control or new treatment arm with P (Zi = 1) = 0.5 where
Ci was generated independently as a multinomial random variable. Subject outcomes Yi were generated from
a binomial distribution with a mean conditional upon treatment assignment Zi and compliance type Ci. We
fixed average outcomes E[Yi(1)|Zi = 1, Ci = a) = E[Yi(1)|Zi = 1, Ci = n] = 0.5 for simplicity, which implies
(by the compound exclusion restriction) that E[Yi(0)|Zi = 0, Ci = a) and E[Yi(0)|Zi = 0, Ci = n] equal 0.5
as well. We also fixed E[Yi(1)|Zi = 1, Ci = c] to be 0.5.
We varied the following parameters: proportions of compliance types, true CACE, and response probabil-
ities for subjects. For the response probabilites, we either let the response probability for all compliance types
equal 0.5, which gave us a missing at random (MAR) missing data mechanism, or we let the response prob-
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abilities depend on latent compliance type (where E(Ri(z)|Zi = z, Ci = c) = E(Ri(z)|Zi = z, Ci = a) = 0.5
but E(Ri(z)|Zi = z, Ci = n) = 0.8 for z ∈ (0, 1)), which gave us a not missing at random (NMAR) missing
data mechanism since response probabilities depend on compliance type which is not observed for all subjects.
Table 3 reports the coverage rates of nominal 95 percent confidence intervals and the bias for ̂CACE.LI Note
that when the response mechanism was MAR, ̂CACELI performed well, giving good coverage and relatively
little bias (Table 3). When the response mechanism was NMAR, the estimator continued to perform well.
In both scenarios, true compliance type probabilities and true CACE values were not critically important in
terms of the behavior of the estimator.
6.2. Numerical Results with Deviations from Latent Ignorability
Next we tested the sensitivity of our estimator to potential outcomes that are no longer indepen-
dent of potential response indicators for subjects in the control arm. We defined the constant f0t =
P (Ri(0)=1|Zi=0,Ci=t,Yi=0)
P (Ri(0)=1|Zi=0,Ci=t,Yi=1)
, where f0t represents the amount of dependence between potential outcomes and
associated response indicators for subjects in the control arm. Note that f0t ≡ 1 corresponds to having
latent ignorability, and distance from f0t to 1 corresponds to the degree of dependence between outcomes
and response indicators. We fixed the true CACE to zero and the response probabilities P (Ri(z) = 1|Zi =
z, Ci = n) = P (Ri(z) = 1|Zi = z, Ci = a) = 0.5 and P (Ri(z) = 1|Zi = z, Ci = c) = 0.7 for z ∈ (0, 1).
We then varied the compliance type proportions and allowed f0t to vary between
1
2 and 2 for all compliance
types in the control arm (where f0n = f0c = f0a). Table 4 reports the coverage rates of nominal 95 percent
confidence intervals and the bias for ̂CACE.LI When f0t was less than one, the estimator underestimated the
true CACE, whereas for values greater than one, the estimator overestimated the true CACE. The further
f0t was from one (meaning the more dependence between outcome and response), the worse the coverage
probabilities. Higher proportions of compliers (relative to always-takers and never-takers) improved the bias
somewhat but slightly worsened the coverage probabilities. Overall we see how sensitive our results can be
when latent ignorability does not hold.
7. Relaxing the Latent Ignorability Assumption
7.1. Defining the Causal Parameters
Once again, for binary outcome Y , we let ψtzd = P [Ci = t|Zi = z, Di = d] and ηzt = E[Yi(z)|Zi = z, Ci =
8 http://biostats.bepress.com/uwbiostat/paper257
t] as in Section 3, where we focus on the CACE (1). We invoke the SUTVA, monotonicity assumption, and
the compound exclusion restriction for never-takers and always-takers. Letting φzty = P (Ri(z) = 1|Zi =
z, Ci = t, Yi(z) = y), we relax the assumption of latent ignorability and incorporate sensitivity parameters
that represent the relationship between the potential outcomes and associated response indicators, where the
sensitivity parameters fzt are defined as
fzt =
φzt0
φzt1
, (1)
and represent the ratio of response probabilities between subjects with outcome Y = 0 versus those with
outcome Y = 1 (for a given assigned treatment z and compliance type t). These parameters are assumed
known and are allowed to take on a plausible range of values in order to assess the sensitivity of the conclusions
of a study to various assumptions regarding the relationship between outcomes and response indicators. If
conclusions are insensitive over a range of logically possible values for fzt, then the number of interpretations
of the data is reduced, and causal conclusions are more defensible.
Under monotonicity, there are no defiers, and under the compound exclusion restrictions, η1a = η0a for
always-takers and η1n = η0n for never-takers. Letting η1a = η0a ≡ ηa and η1n = η0n ≡ ηn, note that ηzt can
be specified in terms of η0c, η1c, ηa, and ηn. Next we note that ψa10 = ψa00 = 0 since one cannot be an
always-taker if one receives the control, and ψn11 = ψn01 = 0 since one cannot be a never-taker if one receives
the new treatment. Similarly ψc01 = ψc10 = 0 since, for compliers, Zi = Di. Since only always-takers have
Di = 1 with Zi = 0 and only never-takers have Di = 0 then Zi = 1, then ψa01 = ψn10 = 1. Also note that
ψc00+ψn00 = ψc11+ψa11 = 1. Then letting ψa ≡ ψa11 and ψn ≡ ψn00, note that ψtzd can be specified in terms
of ψa and ψn. And since the compound exclusion restriction implies that response probabilities for always-
takers (or never-takers) do not depend on treatment assignment, φ0n1(ηn+f0n(1−ηn)) = φ1n1(ηn+f1n(1−ηn))
and φ0a1(ηa+ f1a(1− ηa)) = φ1a1(ηa+ f0a(1− ηa)), so that φzty can be specified in terms of φ0n1, φ1a1, φ1c1,
and φ0c1. Then let θ = (ψa, ψn, ηa, ηn, φ1a1, φ0n1, φ0c1, φ1c1, η0c, η1c).
7.2. Estimation
Let ξzd = P (Zi = z, Di = d), pizd = P (Ri = 1, Zi = z, Di = d), and vzd = P (Yi = 1, Ri = 1, Zi =
z, Di = d). Then with N subjects in the study, let ξˆzd =
1
N
∑n
i=1 1[Zi=z,Di=d], pˆizd =
1
N
∑n
i=1 Ri1[Zi=z,Di=d],
and vˆzd =
1
N
∑n
i=1 YiRi1[Zi=z,Di=d] be unbiased estimators for ξzd, pizd, and vzd , respectively. The following
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result, proved in the online appendix (http://www.stat.sinica.edu.tw/statistica/submission), defines the mo-
ment estimators when latent ignorability is relaxed.
Result 7.1. Under the assumptions of Section 3, the estimators for the parameters in the always-taker and
never-taker subpopulations are:
ψˆa =
ξˆ01
ξˆ11
; ψˆn =
ξˆ10
ξˆ00
ηˆa =
f0avˆ01
pˆi01+(f0a−1)vˆ01
; ηˆn =
f1nvˆ10
pˆi10+(f1n−1)vˆ10
φˆ0a1 =
vˆ01
ξˆ01ηˆa
; φˆ1n1 =
vˆ10
ξˆ10ηˆn
φˆ1a1 =
φˆ0a1(ηˆa+f0a(1−ηˆa))
ηˆa+f1a(1−ηˆa)
; φˆ0n1 =
φˆ1n1(ηˆn+f1n(1−ηˆn))
ηˆn+f0n(1−ηˆn)
The estimators for the parameters in the complier subpopulation are:
φˆ0c1 =
φˆ0n1ψˆnξˆ00(f0cηˆn + f0n(1− ηˆn)) + (1− f0c)vˆ00 − pˆi00
f0cξˆ00(ψˆn − 1)
φˆ1c1 =
φˆ1a1ψˆaξˆ11(f1aηˆa + f1a(1− ηˆa)) + (1− f1c)vˆ11 − pˆi11
f1cξˆ11(ψˆa − 1)
ηˆ1c =
f1c(f1aaˆ01 + f0aaˆ11)
(f1c − 1)(f1aaˆ01 + f0aaˆ11) + f1abˆ01 + f0acˆ01
ηˆ0c =
f0c(f1naˆ10 + f0naˆ00)
(f0c − 1)(f1naˆ10 + f0naˆ00) + f1nbˆ10 + f0ncˆ10
aˆzd = vˆzd(vˆ(1−z)d − pˆizd)
bˆzd = vˆzd(pˆi(1−z)d − pˆizd)
cˆzd = (pˆizd − vˆzd)(pˆi(1−z)d − pˆizd).
The estimator for the CACE derived without the LI assumption, but under known (fixed) sensitivity param-
eters, is ̂CACELI = ηˆ1c − ηˆ0c.
Note that the parameter estimates from the never-taker and always-taker subpopulations generally in-
volve summations over subjects with observed Zi 6= Di; the parameter estimate from the complier subpop-
ulation, ηˆ1c, incorporates a mixture of summations across subjects with observed Zi = Di = 1 (which
consist of a mixture of compliers and always-takers) and subjects with Zi = 0 and Di = 1 (the ob-
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served always-takers); similarly ηˆ0c incorporates a mixture of summations across subjects with observed
Zi = Di = 0 (which consist of a mixture of compliers and never-takers) and subjects with observed Zi = 1
and Di = 0 (the observed never-takers). Note that if f1a = f0a (or f1n = f0n), then neither contribute
to the estimator ̂CACE.LI . Since moment estimators are non-parametric, they can unfortunately be out-
side the (-1,1) range of the estimand of interest. The following theorem, proved in the online appendix
(http://www.stat.sinica.edu.tw/statistica/submission) using the delta method, forms a basis for inference
about ̂CACE.LI
Theorem 7.1 Under the assumptions of Section 3
√
n( ̂CACELI −CACE)→d N (0, δ′V0δ + β′V1β)
as n →∞, for
V0 =


pi00(1− pi00) −pi00pi10 (1− pi00)v00 −pi00v10
−pi10pi00 pi10(1− pi10) −pi10v00 (1− pi10)v10
v00(1 − pi00) −v00pi10 v00(1− v00) −v00v10
−v10pi00 v10(1− pi10) −v10v00 v10(1− v10)

,
V1 =


pi11(1− pi11) −pi11pi01 (1− pi11)v11 −pi11v01
−pi01pi11 pi01(1− pi01) −pi01v11 (1− pi01)v01
v11(1 − pi11) −v11pi01 v11(1− v11) −v11v01
−v01pi11 v01(1− pi01) −v01v11 v01(1− v01)

.
In this result, δ = (δ1, . . . , δ4)
′
is defined as follows:
δ1 = D
−2
0 f0c[f1nv10(v00 − pi10 + f0nv00(pi10 − v10)](f0n(v10 − pi10)− f1nv10),
δ2 = D
−2
0 f0c[f1nv10(v00 − pi10) + f0nv00(pi10 − v10)](f0n(v10 − pi10) − f1nv10) +D
−2
0 f0cf1nv
2
10(f1n−
f0n)(pi00 − pi10),
δ3 = D
−2
0 f0c[f0n(pi10 − v10) + f1nv10]
2(pi00 − pi10),
δ4 = D
−2
0 f0cf1nf0npi
2
10(pi10 − pi00)
for D0 = (f0c − 1)[f1nv10(v00 − pi10) + f0nv00(pi10 − v10)] + (pi00 − pi10)[f1nv10 + f0n(pi10 − v10)] ;
β = (β1, . . . , β4)
′
is defined as follows:
β1 = D
−2
1 f1c[f1av01(v11 − pi01 + f0av11(pi01 − v01)](f0a(v01 − pi01)− f1av01),
β2 = D
−2
1 f1c[f1av01(v11 − pi01) + f0av11(pi01 − v01)](f0a(v01 − pi01)− f1av01) +D
−2
1 f1cf1av
2
01(f1a−
f0a)(pi11 − pi01),
β3 = D
−2
1 f1c[f0a(pi01 − v01) + f1av01]
2(pi11 − pi01),
β4 = D
−2
1 f1cf1af0api
2
01(pi01 − pi11)
for D1 = (f1c − 1)[f1av01(v11 − pi01) + f0av11(pi01 − v01)] + (pi11 − pi01)[f1av01 + f0a(pi01 − v01)].
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7.3. Simulation Study Results
In Table 4, data was generated under the model described in section 6 and therefore ̂CACELI was es-
timated under the assumed known sensitivity parameters. As expected, ̂CACELI performed well in this
scenario with decent coverage and relatively little bias.
8. Influenza Vaccination Study
Among patients who are older or have a high risk of pulmonary disease, observational studies and exper-
imental evidence suggest that those vaccinated with an influenza vaccine have better outcomes (McDonald,
Hui, and Tierney (1992)). A controlled clinical trial to confirm these results has never been performed because
of the ethical problems that arise from withholding the vaccine from patients in the control arm. A solution
to this problem involves performing a controlled clinical trial where the intervention arm increases the use
of the influenza vaccine without changing its use in the control arm. McDonald, Hui, and Tierney (1992)
used this method to study the effects of computer-generated reminders of the influenza vaccine on flu-related
hospitalizations in patients having a high risk for pulmonary disease. For doctors in the intervention arm,
computer reminders were sent out when a patient with a scheduled visit was eligible for a flu shot. Since
the study did not maintain records on the clustering of patients by doctor, we ignore this for the purposes
of illustrating our methods. In this analysis we want to estimate the effect of the flu vaccine on flu-related
hospitalizations (where Yi = 1 if subject i had a flu-related hospitalization and Yi = 0 otherwise). There
were missing outcomes, but no information was given on how the data came to be missing. The data are
provided in Table 2.
Under latent ignorability, (where the sensitivity parameters equal 1 for all compliance types and treat-
ment groups), the estimate of the CACE is 0.01 with 95% confidence interval (-0.25, 0.26) indicating that
there was no significant decrease in hospitalizations as a result of receiving the flu vaccine. We illustrate the
application of the proposed methods by presenting a sensitivity analysis where the CACE is estimated under
differing assumptions regarding the dependence between outcomes and response indicators. Since no infor-
mation was given on how the data came to be missing, we considered four scenarios for testing the sensitivity
of our estimator to deviations in latent ignorability across assigned treatment group and compliance type.
Results from the following scenarios are found in Figure 1 (a-d) where point estimates and 95% confidence
intervals for the CACE are displayed, assuming specified values of the sensitivity parameters. Note that,
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although we use 2-dimensional plots to illustrate the sensitivity analysis, 3-dimensional plots would allow the
user to vary two sensitivity parameters simultaneously.
8.1. Scenario I
To see how sensitive the estimator is to deviations in latent ignorability among compliers in the control
arm, we let f0n = f1n and f0a = f1a, fixed f1c = 1, and allowed f0c to vary between 1/2 and 2. Results are
displayed in Figure 1a. Note that when the sensitivity parameter equals 1 for compliers in the control arm,
latent ignorability is assumed. The estimate of the CACE did not change much as the sensitivity parameters
for control compliers were varied.
8.2. Scenario II
To see how sensitive the estimator is to deviations in latent ignorability among never-takers in the con-
trol arm, we let f0c = f1c = f0a = f1a = f1n = 1, and allowed f0n to vary between 1/2 and 2. Results
are displayed in Figure 1b. The estimate of the CACE changed as the sensitivity parameters were varied,
although there remained no significant decrease in hospitalizations as the confidence intervals all contain zero.
8.3. Scenario III
To see how sensitive the estimator is to deviations in latent ignorability among always-takers in the control
arm, we let f0c = f1c = f0n = f1n = f1a = 1, and allowed f0a to vary between 1/2 and 2. Results are dis-
played in Figure 1c. The estimate of the CACE did not change much as the sensitivity parameters were varied.
8.4. Scenario IV
To see how sensitive the estimator is to deviations in latent ignorability among all subjects in the control
arm, we fixed the sensitivity parameters to 1 for those in the treatment arm (f1n = f1c = f1a ≡ 1) and varied
the sensitivity parameters between 1/2 and 2 for those in the control arm (1/2 < f0n = f0c = f0a < 2).
Results are displayed in Figure 1d. For patients in the control arm, when the probability of observing an
outcome given a flu-related hospitalization differed from the probability of observing the outcome given no
flu-related hospitalization (i.e. f0n = f0c = f0a 6= 1), the estimate of the CACE varied considerably, although
standard errors increased as the dependence increased between the outcome and reponse indicators. In fact,
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it was only when the probability of observing an outcome given a flu-related hospitalization was two times
the probability of observing the outcome given no flu-related hospitalization, that the interval estimate of the
CACE excluded zero: -0.56 (95% CI: -0.92 to -0.20). Thus we find that the CACE point estimate is somewhat
sensitive to reasonable deviations in latent ignorability across treatment group, although the CACE was not
significantly different from zero.
8.5. Summarizing Results
Another way in which a sensitivity analysis can be summarized is a 95% sensitivity interval (Rosenbaum
(1999)) defined here to be the union of all 95% confidence intervals for the CACE for varying values of fzt
that we are confident contain the true fzt. It has a similar property to the confidence interval in that if the
assumption about the range in which the sensitivity parameter lies is correct, then it will contain the true
parameter of interest at least 95% of the time (Rosenbaum, 1999). In the flu vaccine example, there is no
information on how the data came to be missing, but typically this information could help determine an
accurate range for the sensitivity parameters.
9. Discussion
There were some limitations in applying these methods to the flu vaccination study. One may question the
validity of the compound exclusion restriction used to identify the causal parameter of interest, particularly
for the always-takers. While it may make sense to assume that treatment assignment had no direct effect
on outcome (given treatment received) for never-takers, it may not make sense to assume that treatment
assignment had no direct effect on outcome for always-takers. Never-takers may be the healthier patients since
their doctors might not encourage the vaccination under either treatment assignment. For these patients, the
assignment to treatment should not lead doctors to take other measures that could directly affect outcome.
On the other hand, always-takers may be the sicker patients because their doctor might encourage them to get
the flu vaccination regardless of assigned treatment. For these patients, the added impact of being assigned
to the encouragement arm may lead the doctor to encourage other precautionary measures beyond the flu
vaccination which could directly affect the patient’s outcome. The setting or application will determine
which values of the sensitivity parameters are considered plausible. In the case of the flu vaccine study,
no information was given on how the data came to be missing, so we used a wide range of values for the
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sensitivity parameters.
Future research topics could include methods that incorporate baseline covariates which are often col-
lected in a randomized clinical trial, referencing work by Levy, O’Malley, and Normand (2004), as well as
methods that incorporate clustering effects commonly found in encouragement design studies.
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Figure 1: Sensitivity analysis for the influenza vaccination study (point estimates and 95% confidence intervals for
the CACE are displayed): (a) Scenario I: no LI for control compliers; (b) Scenario II: no LI for control never-takers;
(c) Scenario III: no LI for control always-takers; (d) Scenario IV: no LI for all control subjects.
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Table 1: Notation
Notation Specifics General Description
Zi 1 if i assigned treatment Treatment assignment indicator
0 if i assigned control
Di(Zi) 1 if i received treatment under assignment Zi Potential outcome formulation
0 if i received control under assignment Zi of treatment receipt
Di Treatment receipt indicator under
observed assignment
Ci n if Di(0) = 0 and Di(1) = 0 Compliance type principal stratum:
c if Di(0) = 0 and Di(1) = 1 n=never-taker; c=complier;
a if Di(0) = 1 and Di(1) = 1 a=always-taker; d=defier
d if Di(0) = 1 and Di(1) = 0
Yi(Zi) Binary outcome of interest under Potential outcome formulation
assignment Zi of the outcome of interest
Yi Binary outcome of interest under
observed assignment
Ri(Zi) 1 if Yi(Zi) would be observed Response indicator for Yi(Zi)
0 if Yi(Zi) would not be observed
Ri Response indicator for Yi under
observed assignment
ηzt E[Yi(z)|Zi = z, Ci = t]
ψtzd P (Ci = t|Zi = z, Di = d)
ωt P (Ci = t)
φzty E[Ri(z)|Zi = z, Ci = t, Yi(z) = y]
fzt φzt0/φzt1
pizd P (Ri = 1, Zi = z, Di = d)
ξzd P (Zi = z, Di = d)
vzd P (Yi = 1, Ri = 1, Zi = z, Di = d)
Table 2: Influenza Vaccine Data
R=1,Z=0 Y=0 Y=1 Total
D=0 573 49 622
D=1 143 16 159
Total 716 65 781
R=1,Z=1 Y=0 Y=1 Total
D=0 499 47 546
D=1 256 20 276
Total 755 67 822
R=0, Y=· D=0 D=1 Total
Z=0 492 17 509
Z=1 497 9 506
Total 989 26 1015
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Table 3: Simulation results: N=300 with 5,000 replications of the data
compliance Types MAR NMAR
CACE (n, c, a) Coverage Bias Coverage Bias
0 (0.15,0.7,0.15) 94.8 0.002 95.3 0.000
(0.2,0.6,0.2) 95.6 0.002 95.3 -0.001
(0.25,0.5,0.25) 96.5 0.003 95.4 0.003
0.2 (0.15,0.7,0.15) 94.9 0.002 95.3 -0.001
(0.2,0.6,0.2) 95.5 0.005 95.2 0.003
(0.25,0.5,0.25) 96.3 0.006 95.9 0.000
0.4 (0.15,0.7,0.15) 95.4 0.002 95.3 0.001
(0.2,0.6,0.2) 95.8 0.007 95.6 0.003
(0.25,0.5,0.25) 96.6 0.012 95.6 0.006
Table 4: Simulation Results: N=300 with 5,000 replications of the data (CACE = 0; ̂CACELI=estimator assuming
latent ignorability; ̂CACELI=estimator assuming no latent ignorability)
compliance Types ̂CACELI ̂CACELI
f0t (n, c, a) Coverage Bias Coverage Bias
1
2
(0.15,0.7,0.15) 35.4 -0.220 95.8 -0.008
(0.2,0.6,0.2) 38.4 -0.249 95.6 -0.012
(0.25,0.5,0.25) 39.7 -0.292 95.6 -0.012
3
4
(0.15,0.7,0.15) 82.7 -0.093 95.3 -0.001
(0.2,0.6,0.2) 84.8 -0.105 95.5 -0.004
(0.25,0.5,0.25) 85.8 -0.125 95.7 -0.005
1 (0.15,0.7,0.15) 94.8 -0.001 95.2 -0.001
(0.2,0.6,0.2) 95.4 -0.002 95.5 -0.001
(0.25,0.5,0.25) 95.9 -0.001 95.9 -0.004
4
3
(0.15,0.7,0.15) 83.4 0.095 94.9 0.004
(0.2,0.6,0.2) 84.0 0.109 95.5 0.007
(0.25,0.5,0.25) 83.9 0.127 95.7 0.002
2 (0.15,0.7,0.15) 35.6 0.218 95.3 0.009
(0.2,0.6,0.2) 36.4 0.250 95.0 0.009
(0.25,0.5,0.25) 40.0 0.292 95.8 0.016
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Appendix
1. Proof of Theorems 5.1 and 7.1
In order to derive the asymptotic distributions for ̂CACELIand ̂CACE,LI let Xi ≡ (YiRi(1 − Zi)(1 −
Di), YiRi(1− Zi)Di, YiRiZi(1−Di), YiRiZiDi, Ri(1− Zi)(1−Di), Ri(1− Zi)Di, RiZi(1−Di), RiZiDi) and
let p ≡ (v00, v01, v10, v11, pi00, pi01, pi10, pi11) where Xi is a vector of bernoulli random variables with mean p. If
X1, . . . , Xn are i.i.d. random vectors in R
8 with mean p and covariance matrix Σ = E(X− p)(X− p) (where
E(XTX) <∞), then from the multivariate central limit theorem, √n(X¯ − p)→d Nd(0,Σ) where Σ =

v00(1− v00) −v00v01 −v00v10 −v00v11 v00(1 − pi00) −v00pi01 −v00pi10 −v00pi11
−v01v00 v01(1− v01) −v01v10 −v01v11 −v01pi00 −v01(1− pi01) −v01pi10 −v01pi11
−v10v00 −v10v01 v10(1− v10) −v10v11 −v10pi00 −v10pi01 v10(1− pi10) −v10pi11
−v11v00 −v11v01 −v11v10 v11(1− v11) −v11pi00 −v11pi01 −v11pi10 v11(1− pi11)
(1 − pi00)v00 −pi00v01 −pi00v10 −pi00v11 pi00(1− pi00) −pi00pi01 −pi00pi10 −pi00pi11)
−pi01v00 (1− pi01)v01 −pi01v10 −pi01v11 −pi01pi00 pi01(1− pi01) −pi01pi10 −pi01pi11)
−pi10v00 −pi10v01 (1− pi10)v10 −pi10v11 −pi10pi00 −pi10pi01 pi10(1 − pi10) −pi10pi11)
−pi11v00 −pi11v01 −pi11v10 (1− pi11)v11 −pi11pi00 −pi11pi01 −pi11pi10 pi11(1− pi11)


1.1 Proof of Theorem 5.1
Using the multivariate delta method, the asymptotic distributions for ηˆ0c and ηˆ0c are:
√
n(ηˆ1c − η1c)→d N (0, δ′Σδ) where δ′ = (0, −1pi11−pi01 , 0,
1
pi11−pi01
, 0, v11−v01
(pi11−pi01)2
, 0, v01−v11
(pi11−pi01)2
) and
√
n(ηˆ0c − η0c)→d N (0, β′Σβ) where β′ = ( −1pi10−pi00 , 0, 1pi10−pi00 , 0,
v10−v00
(pi10−pi00)2
, 0, v00−v10(pi10−pi00)2 , 0)
where V1 = δ
′
Σδ and V0 = β
′
Σβ are defined in section 4. Then noting that
√
n(ηˆ1c− η1c) and
√
n(ηˆ0c − η0c)
are asymptotically independent since δ
′
Σβ = 0, we can use Slutsky’s theorem to derive the asymptotic dis-
tribution for ̂CACELIas in Theorem 5.1.
1.2 Proof of Theorem 7.1
Using the multivariate delta method, the asymptotic distributions for ηˆ1c and ηˆ0c are
√
n(ηˆ1c − η1c) →d
N (0, δ
′
Σδ), where δ
′
= (0, δ1, 0, δ2, 0, δ3, 0, δ4) for δ defined in Theorem 7.1, and
√
n(ηˆ0c−η0c)→d N (0, β′Σβ)
where β
′
= (0, β1, 0, β2, 0, β3, 0, β4) for β defined in Theorem 7.1. Again noting that
√
n(ηˆ1c − η1c) and
√
n(ηˆ0c− η0c) are asymptotically independent, we can use Slutsky’s theorem to derive the asymptotic distri-
bution for ̂CACELIas in Theorem 7.1.
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2. Proof of Result 7.1
For ψn = P (C = n|Z = 0, D = 0) note that under randomization P (C = n, Z = 0) = P (C = n, Z = 1)
and since never-takers by definition have D = 0, then we expect P (C = n, Z = 0, D = 0) = P (C = n, Z =
1, D = 0). Similarly for always-takers, P (C = a, Z = 1, D = 1) = P (C = a, Z = 0, D = 1).
Therefore:
ψn =
P (C = n, Z = 0, D = 0)
P (Z = 0, D = 0)
=
P (C = n, Z = 1, D = 0)
P (Z = 0, D = 0)
=
P (Z = 1, D = 0)
P (Z = 0, D = 0)
ψa =
P (C = a, Z = 1, D = 1)
P (Z = 1, D = 1)
=
P (C = a, Z = 0, D = 1)
P (Z = 1, D = 1)
=
P (Z = 0, D = 1)
P (Z = 1, D = 1)
Thus we can obtain the following estimators for ψn and ψa:
ψˆn =
ξˆ10
ξˆ00
; ψˆa =
ξˆ01
ξˆ11
Then note the following relationship:
vzd = P (Y = 1, R = 1, Z = z, D = d)
=
∑
t∈(n,c,a)
P (R = 1, Z = z, D = d, C = t, Y = 1)
=
∑
t∈(n,c,a)
P (R = 1|Z = z, D = d, C = t, Y = 1)P (Y = 1|Z = z, D = d, C = t)
P (C = t|Z = z, D = d)P (Z = z, D = d)
⇔ vzd
ξzd
=
∑
t∈(n,c,a)
P (R = 1|Z = z, D = d, C = t, Y = 1)
P (Y = 1|Z = z, D = d, C = t)P (C = t|Z = z, D = d)
=
∑
t∈(n,c,a)
φzt1ηztψtzd (2)
Also note the following relationship:
pizd
ξzd
= P (R = 1|Z = z, D = d)
=
∑
t∈(n,c,a)
P (R = 1|Z = z, D = d, C = t)P (C = t|Z = z, D = d)
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=
∑
t∈(n,c,a)
(
∑
y∈(0,1)
P (R = 1|Z = z, D = d, C = t, Y = y)P (Y = y|Z = z, D = d, C = t))
P (C = t|Z = z, D = d)
=
∑
t∈(n,c,a)
P (R = 1|Z = z, D = d, C = t, Y = 1)P (Y = 1|Z = z, D = d, C = t)
P (C = t|Z = z, D = d) + P (R = 1|Z = z, D = d, C = t, Y = 0)
P (Y = 0|Z = z, D = d, C = t)P (C = t|Z = z, D = d)
=
∑
t∈(n,c,a)
φzt1ηztψtzd + φzt0(1− ηzt)ψtzd
=
∑
t∈(n,c,a)
φzt1ηztψtzd + fztφzt1(1− ηzt)ψtzd
=
∑
t∈(n,c,a)
φzt1ψtzd(ηzt + fzt(1− ηzt)) (3)
Letting (z, d) equal (0, 1) and (1, 0) in expression (3) above and solving for φ0a1 and φ1n1 we get:
φ0a1 =
v01
ξ01ηa
; φ1n1 =
v10
ξ10ηn
(4)
Letting (z, d) equal (0, 1) and (1, 0) in expression (4) above and substituting the expressions from (5):
pi01
ξ01
=
v01
ξ01ηa
(ηa + f0a(1− ηa)); pi10
ξ10
=
v10
ξ10ηn
(ηn + f1n(1− ηn))
Then solving for ηa and ηn above, we obtain the following estimators:
ηˆa =
f0avˆ01
pˆi01 + (f0a − 1)vˆ01 ; ηˆn =
f1nvˆ10
pˆi10 + (f1n − 1)vˆ10
We can then obtain estimators for φ0a1 and φ1n1:
φˆ0a1 =
vˆ01
ξˆ01ηˆa
; φˆ1n1 =
vˆ10
ξˆ10ηˆn
Using the exclusion criteria for never-takers and always-takers and (2), note that:
φ0n1(ηn + f0n(1− ηn)) = φ1n1(ηn+ f1n(1− ηn))
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φ1a1(ηa + f1a(1− ηa)) = φ0a1(ηa + f0a(1− ηa))
Then solving for φ0n1 and φ1a1 above we obtain the following estimators:
φˆ1a1 =
φˆ0a1(ηˆa + f0a(1− ηˆa))
ηˆa + f1a(1− ηˆa) ; φˆ0n1 =
φˆ1n1(ηˆn + f1n(1− ηˆn))
ηˆn + f0n(1− ηˆn)
Letting (z, d) = (0, 0) in expressions (3) and (4) and solving for η0c and φ0c1 we obtain:
φ0c1 =
φ0n1ψnξ00(f0cηn + f0n(1− ηn)) + (1− f0c)v00 − pi00
ξ00f0c(ψn − 1)
η0c =
f0c(φ0n1ψnξ00ηn − v00)
φ0n1ψnξ00(f0cηn + f0n(1− ηn)) + (1− f0c)v00 − pi00
Letting (z, d) = (1, 1) in expression (3) and (4) and solving for η1c and φ1c1 we obtain:
φ1c1 =
φ1a1ψaξ11(f1aηa + f1a(1− ηa)) + (1− f1c)v11 − pi11
ξ11f1c(ψa − 1)
η1c =
f1c(φ1a1ψaξ11ηa − v11)
φ1a1ψaξ11(f1aηa + f1a(1− ηa)) + (1− f1c)v11 − pi11
Substituting in the expressions for φˆ0n1, ψˆn, ηˆn, φˆ1a1, ψˆa, and ηˆa we obtain the following expressions for ηˆ0c
and ηˆ1c (which reduce to the expressions found in Result 7.1):
ηˆ0c =
f0c[f1nvˆ10(vˆ00 − pˆi10) + f0nvˆ00(pˆi10 − vˆ10)]
(f0c − 1)[f1nvˆ10(vˆ00 − pˆi10) + f0nvˆ00(pˆi10 − vˆ10)] + f1nvˆ10(pˆi00 − pi10) + f0n(pˆi10pˆi00 − pˆi210 − vˆ10pˆi00 + vˆ10pˆi10)
ηˆ1c =
f1c[f1avˆ01(vˆ11 − pˆi01) + f0avˆ11(pˆi01 − vˆ01)]
(f1c − 1)[f1avˆ01(vˆ11 − pˆi01) + f0avˆ11(pˆi01 − vˆ01)] + f1avˆ01(pˆi11 − pi01) + f0a(pˆi01pˆi11 − pˆi201 − vˆ01pˆi11 + vˆ01pˆi01)
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